GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Profitability Rank

BrainsWay (BrainsWay) Profitability Rank : 2 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Profitability Rank?

BrainsWay has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

BrainsWay's Operating Margin % for the quarter that ended in Dec. 2023 was 2.04%. As of today, BrainsWay's Piotroski F-Score is 6.


Competitive Comparison of BrainsWay's Profitability Rank

For the Medical Devices subindustry, BrainsWay's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Profitability Rank Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Profitability Rank distribution charts can be found below:

* The bar in red indicates where BrainsWay's Profitability Rank falls into.



BrainsWay Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

BrainsWay has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BrainsWay's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.184 / 9.029
=2.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

BrainsWay has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

BrainsWay Ltd operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


BrainsWay Profitability Rank Related Terms

Thank you for viewing the detailed overview of BrainsWay's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.